Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 653 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Total Cholesterol Clear all

Conditions: Hyperlipidemias
Interventions: Lapaquistat acetate and fenofibrate, Fenofibrate; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 32
States / cities: Huntsville, Alabama • Sierra Vista, Arizona • Beverly Hills, California + 29 more

Conditions: Hypersensitivity Pneumonitis
Interventions: Re-imagining Interventions for Support and Education in Hypersensitivity Pneumonitis (RISE-HP), Staying Well; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Prevention of Atherosclerotic Cardiovascular Disease
Interventions: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 79 Years
Enrollment: 14,012 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 241
States / cities: Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 187 more

Conditions: Stroke, Intracranial Atherosclerosis, Intraplaque Hemorrhage
Interventions: Alirocumab, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Dyslipidemias, High Cholesterol, Hypercholesterolemia
Interventions: Obicetrapib 5mg, Ezetimibe 10mg, Placebo; Drug · Other
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 3
States / cities: Lincoln, California • Evanston, Illinois • Houston, Texas

Conditions: Cholesterol, Elevated, Elevated Cholesterol
Interventions: No Intervention; Other
Lead sponsor: ProgenaBiome; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Ventura, California

Conditions: Hyperlipidemia, Hypercholesterolemia, Coronary Heart Disease, Cardiovascular Disease
Interventions: Simvastatin; Drug
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 30 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2002
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Lysosomal Acid Lipase Deficiency, Cholesterol Ester Storage Disease
Interventions: enzyme analysis; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cardiovascular Disease
Interventions: AZD0780, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 3,103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 101
States / cities: Huntsville, Alabama • Irondale, Alabama • Mobile, Alabama + 92 more

Conditions: Metabolic Cardiovascular Syndrome
Interventions: High-Tech Education, Low-Tech Education; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: Astaxanthin, Placebo; Dietary Supplement · Other
Lead sponsor: LycoRed Ltd.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Richardson, Texas

Conditions: Cardiovascular Disease
Interventions: Almonds; Other
Lead sponsor: Penn State University; Other
Eligibility: 30 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: ASCVD, Elevated Cholesterol
Interventions: Inclisiran Sodium, Placebo; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,561 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 145
States / cities: Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 110 more

Conditions: Hypercholesterolemia
Interventions: MD-0727; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • Walnut Creek, California + 17 more

Conditions: Hypercholesterolemia
Interventions: Ezetimibe 10 mg, Ezetimibe 5 mg; Drug
Lead sponsor: Bronx VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Diabetes, Heart Disease, Hypertension
Interventions: CARIÑO Project, Enhanced Usual Care; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 35 Years to 70 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Lipoidosis
Interventions: SCH-58235; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metabolic Syndrome X, Prediabetic State, Insulin Resistance, Obesity, Metabolic Diseases
Interventions: Dietary supplement for weight loss, Education and counseling for weight loss; Drug · Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 60 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions: bempedoic acid; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Tampa, Florida • Louisville, Kentucky • Cincinnati, Ohio

Conditions: Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases, Hyperlipoproteinemia
Interventions: LY3561774, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Waterbury, Connecticut • Oxon Hill, Maryland • Fall River, Massachusetts + 3 more

Conditions: Chronic Kidney Diseases
Interventions: Dietary education program; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Rochester, New York

Conditions: Hypercholesterolemia
Interventions: Simvastin, Computer-based decision support technology; Drug · Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 45 Years to 70 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Familial Hypercholesterolemia
Interventions: Evolocumab; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Drug Interactions
Interventions: Rosuvastatin, Rosuvastatin + BAY1817080; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Daytona Beach, Florida

Search by objective public record fields.

Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels

Reimagining Interventions for Support and Education in Hypersensitivity Pneumonitis

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

Randomized Study of Obicetrapib in Combination With Ezetimibe

A Pilot Study to Explore the Role of Gut Flora in Elevated Cholesterol

Cholesterol and Pharmacogenetic Study

Identification of Undiagnosed Lysosomal Acid Lipase Deficiency

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

Metabolic Syndrome Diagnosis and Education Trial

A Study to Evaluate the Effect of Astaxanthin in Healthy Participants

Effects of Almonds on Cardiovascular Risk Factors

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia

Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe)

Miami Healthy Heart Initiative a Behavioral Study on Cardiovascular Risk Factors

SCH-58235 (Ezetimibe) to Treat Homozygous Sitosterolemia

Education, Counseling, and Drug Therapy to Reduce Symptoms of Metabolic Syndrome

Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)

A Study of LY3561774 in Participants With Mixed Dyslipidemia

Effects of a Whole-food, Plant-based Nutrition Program on BP and Potassium in Subjects With CKD

Systematic Management of High Cholesterol Utilizing Computer Monitoring

Impact of LDL-cholesterol Lowering on Platelet Activation

Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants